Stock 0RK9 ALLIGATOR BIOSCIENCE AB
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Alligator Bioscience AB London S.E.

Equities

0RK9

SE0000767188

Market Closed - London S.E.
Other stock markets
 15:52:01 17/11/2021 GMT 		5-day change 1st Jan Change
2.508 SEK -66.28% Intraday chart for Alligator Bioscience AB +98.14% +303.28%
08:00am Alligator Bioscience Announces Results from the Ongoing Optimize-1 Trial CI
06-20 Alligator Bioscience AB to Present Positive Phase 2 Data on Mitazalimab in Pancreatic Cancer at ESMO GI 2024 CI

Highlights

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Alligator Bioscience Announces Results from the Ongoing Optimize-1 Trial
CI
Alligator Bioscience AB to Present Positive Phase 2 Data on Mitazalimab in Pancreatic Cancer at ESMO GI 2024
CI
Alligator Bioscience Announces Publication of on Its Lead Drug Candidate Positive Phase 2 Data Mitazalimab in First Line Metastatic Pancreatic Cancer in the Lancet Oncology
CI
Alligator Bioscience to Present Positive Phase 2 Mitazalimab Data in Pancreatic Cancer at 2024 ASCO Annual Meeting
CI
Alligator Bioscience Announces Initiation of an Investigator-Initiated Phase 1 Clinical Study of Mitazalimab in Local Advanced Pancreatic Cancer
CI
Alligator Bioscience AB Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Alligator Bioscience and Orion Corporation Announces Exercise of Development Option Under 2021 Research Collaboration and License Agreement
CI
Alligator Bioscience Announces Publication of a Scientific Article Featuring Its Novel Bispecific Antibody Format RUBY® in the Peer-Reviewed Journal mAbs
CI
Alligator Bioscience and Aptevo Therapeutics Announce Positive Interim Data of Dose Escalation Phase of ALG.APV-527 Phase 1 Study in Solid Tumor Cancers Expressing Tumor Antigen 5T4
CI
Alligator Bioscience AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023
CI
Alligator Bioscience Announces Cost Reduction Program to Align Key Priorities and Maximize Long-Term Value Creation
CI
Alligator Bioscience Announces Positive Top-Line Results from the Optimize-1 Phase 2 Study of the Company's Lead Asset Mitazalimab in 1st Line Metastatic Pancreatic Cancer
CI
Alligator Bioscience AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Alligator Bioscience Grants New Composition of Matter Patent in Europe for Mitazalimab
CI
Alligator Bioscience Obtains Orphan Status for Pancreatic Cancer Therapy in EU
MT
Alligator Bioscience Advances Research Partnership With Orion
MT
Alligator Bioscience AB Announces Technical Feasibility in the Second Program Under the Research Collaboration and License Agreement with Orion Corporation
CI
Alligator Bioscience AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
CI
Alligator Bioscience AB Announces Phase II Results Indicate Durability of Response for Alligator's CD40 Agonist
CI
Alligator Bioscience Announces Positive Second Interim Results from the Ongoing Optimize-1 Phase 2 Study of the Lead Asset Mitazalimab in 1st Line Metastatic Pancreatic Cancer
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ATORX Stock
  4. 0RK9 Stock
  5. News Alligator Bioscience AB
  6. Highlights